Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: darbyred who wrote (1823)	7/10/2001 8:30:20 PM
From: muddphudd	Read Replies (1) \| Respond to of 1837

Thanks for your thoughts. They make for a difficult decision. Is there any chance that someone else will step in with a better offer? I think DRMD sold out to low. There pipeline of generics and Cenestin are certainly worth more. I am still not sure what to do with the stock. Any other insights are welcomed. Regards.

To: darbyred who wrote (1823)	7/10/2001 11:22:44 PM
From: vestor	Read Replies (1) \| Respond to of 1837

The costs related to promoting a generic is far less than promoting a new drug. Already the major drug store chains are aware that generic Prozac is coming. HMO's etc. will not let subscribers ignore the generic. To say that the costs to promote generic Prozac could be as high as the cost to promote Cenestin is not correct. Many generic companies do not even have a sales force because natural forces prompt drug store chains to stock-up especially if you are the first generic. Given the 2001 annual sales of Prozac I would be surprised if the anouncement that generic Prozac is being shipped would have no effect on BRL's share price. Further, DRMD has said they anticipate three FDA approvals by years end and perhaps BRL may be expecting a couple. In my case I am investing and thus hve a longer term horizon. Instant immediate gratification is not a requirement. A falling share price due to overal market conditions and unchanged fundamentals only signals to me a time to add to positions. There were many who said 8 was the top and more who said at 12 we would never see 13..... ultimately the fundamental prevail. We need not see news come out every week. Be patient,my analysis is saying you have good reason to become part of the BRL/DRMD merger if you have at least a one year holding period. Regarding the matter of reasonable PE. As per IBD the industry avg is 85. BRL is around 40 and is of course not considering generic Prozac. What reasonable/reliable respected source provides you with another reasonable/avg PE? Further, perhaps, a PE's reasonableness should be considered in the light of their growth and anticipated growth. (GARP)